Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DALGAN vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dalgan (generic: dezocine) is a mixed opioid agonist-antagonist that acts as a partial agonist at mu-opioid receptors and a full agonist at kappa-opioid receptors, producing analgesia through modulation of pain signaling in the central nervous system. It also exhibits antagonist activity at mu receptors at higher doses, limiting its abuse potential and respiratory depression compared to full agonists.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Management of moderate to severe pain (FDA-approved),Preoperative analgesia,Postoperative pain relief,Adjunct to anesthesia
Mild to moderate pain,Fever
Oral: 50-100 mg every 6-8 hours; maximum 400 mg/day. IV: 25-50 mg every 6 hours; maximum 200 mg/day.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal half-life: 2–3 hours; clinically may be prolonged in renal impairment.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Primarily hepatic via glucuronidation and N-demethylation. Involves UDP-glucuronosyltransferase (UGT) enzymes and possibly cytochrome P450 (CYP) 3A4 contributes to minor metabolism to inactive metabolites.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Renal: ~90% as unchanged drug and glucuronide conjugates; biliary/fecal: ~10%.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
~20% bound to albumin and alpha-1-acid glycoprotein.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
3–5 L/kg; suggests extensive tissue distribution.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral: 40–60% (first-pass metabolism); IM: ~70%; rectal: ~50%.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
GFR 10-50 m L/min: administer 50-75% of usual dose every 8-12 hours. GFR <10 m L/min: administer 50% of usual dose every 12 hours.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% and extend interval to every 8-12 hours. Child-Pugh C: reduce dose by 75% and extend interval to every 12 hours.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Oral: 0.5-1 mg/kg every 4-6 hours; maximum 4 mg/kg/day. IV: 0.3-0.5 mg/kg every 6 hours; maximum 2 mg/kg/day.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Initiate at 50% of adult dose; titrate slowly to response; maximum 300 mg/day. Avoid in patients with creatinine clearance <30 m L/min.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS. Dalgan exposes users to risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Serious, life-threatening, or fatal respiratory depression may occur. Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Life-threatening respiratory depression: monitor closely, especially during initiation or dose escalation,Opioid-induced hyperalgesia: paradoxical increase in pain sensitivity,Adrenal insufficiency: monitor for symptoms of hypocortisolism,Severe hypotension: risk in hypovolemic patients or those with compromised blood pressure,Seizures: may exacerbate seizure disorders,Risks of use in patients with head injury or increased intracranial pressure,Avoid abrupt discontinuation: taper dose to prevent withdrawal syndrome,May precipitate withdrawal in opioid-dependent patients due to antagonist activity at mu receptors
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to dezocine or any component of the formulation,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid grapefruit juice as it may increase dezocine levels via CYP3A4 inhibition. No other significant food interactions reported; take with or without food. Limit alcohol to prevent additive CNS depression.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
FDA Pregnancy Category C: First trimester risk of major malformations unknown; animal studies show fetal toxicity at high doses. Second/third trimester: risk of neonatal withdrawal syndrome if prolonged use near term. Avoid unless benefit outweighs risk.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Excreted in breast milk; M/P ratio not established. Limited human data; potential for infant sedation and withdrawal. Use only if essential, monitor infant for drowsiness and poor feeding.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No standard dose adjustments; pharmacokinetic changes (increased clearance, volume of distribution) may require higher doses to maintain efficacy. Use lowest effective dose; avoid in first trimester if possible. Taper to prevent withdrawal.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Dalgan (dezocine) is a mixed agonist-antagonist opioid with ceiling effect for respiratory depression; use caution in opioid-tolerant patients due to risk of precipitating withdrawal. Not recommended for prolonged use due to potential for dependence. Monitor for hypotension and bradycardia, especially in elderly or volume-depleted patients.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid driving or operating heavy machinery until you know how this medication affects you.,Do not consume alcohol or other central nervous system depressants while taking this drug.,Report any signs of withdrawal (e.g., anxiety, sweating, cramping) or allergic reaction (rash, difficulty breathing) immediately.,Store at room temperature away from moisture and heat; keep out of reach of children.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DALGAN vs ACEPHEN, answered by our medical review team.
DALGAN is a Opioid Analgesic that works by Dalgan (generic: dezocine) is a mixed opioid agonist-antagonist that acts as a partial agonist at mu-opioid receptors and a full agonist at kappa-opioid receptors, producing analgesia through modulation of pain signaling in the central nervous system. It also exhibits antagonist activity at mu receptors at higher doses, limiting its abuse potential and respiratory depression compared to full agonists.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DALGAN and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DALGAN is: Oral: 50-100 mg every 6-8 hours; maximum 400 mg/day. IV: 25-50 mg every 6 hours; maximum 200 mg/day.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DALGAN and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DALGAN is classified as Category C. FDA Pregnancy Category C: First trimester risk of major malformations unknown; animal studies show fetal toxicity at high doses. Second/third trimester: risk of neonatal withdrawal. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.